Business Context and Reporting Period
This Form 8-K filing by Cara Therapeutics, Inc. (trading symbol: CARA) reports on the Annual Meeting of Stockholders held on June 4, 2019. The registrant is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Dr. Jeffrey L. Ives: Elected with 10,383,585 votes for, 5,345,664 votes withheld, and 15,714,667 broker non-votes.
- Mr. Christopher Posner: Elected with 15,641,126 votes for, 88,123 votes withheld, and 15,714,667 broker non-votes.
- Both directors were elected to serve until the 2022 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2019.
- Votes For: 31,147,675
- Votes Against: 216,461
- Votes Abstain: 79,780
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the Proxy Statement filed on April 24, 2019, for detailed biographies of the newly elected directors.
- Confirm the engagement letter terms with Ernst & Young LLP for the 2019 fiscal year.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.